arrow
D

Daniel J. McGrail

Lerner Research Institute
H指数:35
被引数:4,730

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Tumor ecosystem and microbiome features associated with efficacy and resistance to avelumab plus chemoradiotherapy in head and neck cancer

头颈癌中与avelumab联合化放疗疗效及耐药性相关的肿瘤生态系统和微生物组特征

2026-01-020
PRE
Neutrophil to lymphocyte ratio varies in magnitude and biomarker utility based on patient demographics

Ang W, Kerr TD, Kodiboyena A, Valero C, Vos JL, Makarov V, 等. 中性粒细胞与淋巴细胞比值根据患者人口统计学特征在幅度和生物标志物效用方面存在差异。临床研究杂志。(2025)。doi: 10.1172/jci198948

2026-01-022
OA
Intratumoral bacteria are immunosuppressive and promote immunotherapy resistance in head and neck squamous cell carcinoma

肿瘤内细菌具有免疫抑制性,并促进头颈部鳞状细胞癌的免疫治疗耐药性。

2026-01-020
OAAI
Accumulation of succinate suppresses de novo purine synthesis through succinylation-mediated control of the mitochondrial folate cycle

琥珀酸盐的积累通过琥珀酰化介导的控制线粒体叶酸循环来抑制从头嘌呤合成。

2025-10-280
PRE
Tumor Intrinsic METTL5 Modulates ATF4 Translation to Prevent T Cell-Induced Ferroptosis in Ovarian Cancer

肿瘤内源性METTL5调控ATF4翻译以防止T细胞诱导的铁死亡在卵巢癌中发生

2025-10-030
OAAI
Chemosensitization is not associated with improved adjuvant radiation outcomes for cutaneous squamous cell carcinoma: a dual-center retrospective cohort study

化学增敏与皮肤鳞状细胞癌辅助放疗结果的改善无关:一项双中心回顾性队列研究

2025-09-110
PRE
Exploring TROP2 expression in oropharyngeal squamous cell carcinoma: Association with prognosis and tumor immune microenvironment composition

探索TROP2在口咽鳞状细胞癌中的表达:与预后的关联及肿瘤免疫微环境组成的关联

2025-08-260
PRE
KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer

KEAP1和STK11/LKB1突变增强KRAS突变非小细胞肺癌对ATR抑制的易感性

2025-07-100
OAAI
TROP2 Expression in Salivary Gland Adenoid Cystic Carcinoma (ACC) According to Histologic Subtype: Therapeutic Implications

TROP2在唾液腺腺样囊性癌(ACC)中的表达:根据组织学亚型及其治疗意义

2025-07-080
OA
Building research infrastructure to advance precision medicine in colorectal cancer

构建研究基础设施以推进结直肠癌精准医学

2025-06-010
OAAI
UBA1 inhibition sensitizes cancer cells to PARP inhibitors

UBA1抑制使癌细胞对PARP抑制剂更敏感

2024-12-011
PRE
Clinical and biomarker analyses of intratumoral CD40 agonist sotigalimab in combination with pembrolizumab in metastatic melanoma: A phase I/II trial

在转移性黑色素瘤中,肿瘤内注射CD40激动剂sotigalimab联合pembrolizumab的临床与生物标志物分析:一项I/II期临床试验

2024-09-010
PRE
Notch inhibitor AL101 prior to surgery in patients (pts) with Notch1 activated adenoid cystic carcinoma (ACC): Safety and efficacy in a window of opportunity study

Notch抑制剂AL101在Notch1激活的腺样囊性癌(ACC)患者术前治疗中的安全性及有效性:一项机会窗口研究

2024-09-010
PRE